Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

Search results for cangrelor in Related Substance Name (approximate match)

Showing 1 - 8 of 8 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

CANGRELOR

6AQ1Y404U7

Search for Structure

Status:

US Approved Rx (2015)

Source:

NDA204958

(2015)

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204958

First approved in 2015

Source:

NDA204958

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204958

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Uracil nucleotide/cysteinyl leukotriene receptor

P2Y purinoceptor 12

Conditions:

Myocardial infarction

Degenerative brain disease

Cangrelor is a P2Y12 inhibitor that has been approved as an antiplatelet drug. It is marketed in the US under the brand name Kengreal and in Europe as Kengrexal. Cangrelor is an intravenous, direct-acting reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention.

(2R,3S,4R,5R)-2-(HYDROXYMETHYL)-5-(6-(2-METHYLSULFANYLETHYLAMINO)-2-(3,3,3-TRIFLUOROPROPYLSULFANYL)PURIN-9-YL)TETRAHYDROFURAN-3,4-DIOL

39WQB3ZG8Z

Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

(2R,3S,4R,5R)-2-(HYDROXYMETHYL)-5-(6-(2-METHYLSULFINYLETHYLAMINO)-2-(3,3,3-TRIFLUOROPROPYLSULFANYL)PURIN-9-YL)TETRAHYDROFURAN-3,4-DIOL

597NKQ6BTS

Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (EPIMERIC)

9H-PURIN-6-AMINE, N-(2-(METHYLTHIO)ETHYL)-2-((3,3,3-TRIFLUOROPROPYL)THIO)-

4N6RMF8XHB

Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

AR-C90441XX

AU2535SHH9

Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (RACEMIC)

PLASMA PROTEIN FRACTION (HUMAN)

6D53G0FD0Z

Status:

Possibly Marketed Outside US

Source:

Octaplasma by Octapharma Pharmazeutika Produktionsges M B H [Canada]

Source URL:

https://www.drugbank.ca/drugs/DB13968

First approved in 2013

Source:

BLA125416

Source URL:

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=998415d8-9bbe-e5b8-c3b0-3ba0344faacb

Class:

MIXTURE

P2Y PURINOCEPTOR 12

O0QUP6NQ1H

Subunit 1 (342) Similarity Search

Sequence Search

Subunit 1 (342) Similarity Search

Status:

Other

Class:

PROTEIN

CANGRELOR TETRASODIUM

2144G00Y7W

Search for Structure

Status:

US Approved Rx (2015)

Source:

NDA204958

(2015)

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204958

First approved in 2015

Source:

NDA204958

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204958

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Uracil nucleotide/cysteinyl leukotriene receptor

P2Y purinoceptor 12

Conditions:

Myocardial infarction

Degenerative brain disease

Cangrelor is a P2Y12 inhibitor that has been approved as an antiplatelet drug. It is marketed in the US under the brand name Kengreal and in Europe as Kengrexal. Cangrelor is an intravenous, direct-acting reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention.

Structure of CANGRELOR

ABSOLUTE

Structure of (2R,3S,4R,5R)-2-(HYDROXYMETHYL)-5-(6-(2-METHYLSULFANYLETHYLAMINO)-2-(3,3,3-TRIFLUOROPROPYLSULFANYL)PURIN-9-YL)TETRAHYDROFURAN-3,4-DIOL

ABSOLUTE

(2R,3S,4R,5R)-2-(HYDROXYMETHYL)-5-(6-(2-METHYLSULFANYLETHYLAMINO)-2-(3,3,3-TRIFLUOROPROPYLSULFANYL)PURIN-9-YL)TETRAHYDROFURAN-3,4-DIOL

Structure of (2R,3S,4R,5R)-2-(HYDROXYMETHYL)-5-(6-(2-METHYLSULFINYLETHYLAMINO)-2-(3,3,3-TRIFLUOROPROPYLSULFANYL)PURIN-9-YL)TETRAHYDROFURAN-3,4-DIOL

EPIMERIC

(2R,3S,4R,5R)-2-(HYDROXYMETHYL)-5-(6-(2-METHYLSULFINYLETHYLAMINO)-2-(3,3,3-TRIFLUOROPROPYLSULFANYL)PURIN-9-YL)TETRAHYDROFURAN-3,4-DIOL

Structure of 9H-PURIN-6-AMINE, N-(2-(METHYLTHIO)ETHYL)-2-((3,3,3-TRIFLUOROPROPYL)THIO)-

ACHIRAL

9H-PURIN-6-AMINE, N-(2-(METHYLTHIO)ETHYL)-2-((3,3,3-TRIFLUOROPROPYL)THIO)-

Structure of AR-C90441XX

RACEMIC

Mixture

PLASMA PROTEIN FRACTION (HUMAN)

Protein

P2Y PURINOCEPTOR 12

Structure of CANGRELOR TETRASODIUM

ABSOLUTE

CANGRELOR TETRASODIUM

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1